Request the brochure

* Denotes Required Field
Theme: Promoting Biologics Drug Development in China at Lower Cost, Higher Speed, and Superior Quality with Higher Level of Innovation and Frontier Technology
The biologics market is evolving with rapid development. In the past year, sales of biologics have increased to 70% among top 10 blockbusters. Caner immunotherapy, cell therapies and Ebola vaccines have made substantial progress. However, with patent cliff for some top biologics in recent years, there’ll be around 10 biologics going off patent in the next four years and meantime it will unleash USD 60 billion market size for biosimilars. In 2015, EMA approved over 20 biosilimars and FDA also accepted filings from Sandoz which is biosimilar arm of Novartis. As the most important pharma market, biosimilar sector is one of focal points for China pharma industry. CFDA released long-awaited biosimilar guideline and new Chinese pharmacopeia in 2015 which brings unprecedented growth opportunities to China biologics industry. Read more...

Eminent Speakers

To be announced soon…..,

Event Features

  • 1 main conference and 3 focused streams
  • 40+ high level pharma and biotech speakers
  • 200+ delegates from over 15 countries and regions
  • 80% on average attendees are CEO/VP/director level decision makers
  • 70% above are biopharma R&D and bioprocess related end users (biopharma, b

Key Topics

  • China’s Biologics Regulation and Industry Trends
  • FDA’s and EMA’s IND and BLA Filings for Global Expansion
  • Biosimilars: Development Strategy, Market Access and Commercialization
  • Overcoming Regulation & CMC Hurdles for Biosimilar Development
  • Protein Expression, Purification, & Characterization
  • Antibody-Drug Conjugates Development and Frontier Technology
Produced by
Media Partners